Masimo held a 23.1% share of the US pulse oximetry systems market in 2025, as per GlobalData analysis.

Danaher Corporation (NYSE:DHR) announced it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: ...

Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share. The transaction, announced February 17, 2026, ...

Masimo MASI recently entered into a definitive agreement, pursuant to which it will be acquired by the global conglomerate, ...

Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics ...

By Sabrina Valle and Gnaneshwar Rajan Feb 17 (Reuters) - Danaher, a $150 billion U.S. company that makes tools used in developing and testing medicines, on Tuesday agreed to buy Masimo for $9.9 ...

Masimo is undergoing an organizational realignment to sharpen its focus on core healthcare offerings. ・A U.S. jury ordered Apple to pay Masimo $634 million in damages in the patent infringement case; ...

Masimo SET ® Is the Primary Pulse Oximetry at All 10 Top U.S. Hospitals, Monitors More Than 200 Million Patients a Year, and Has Been Shown to Have Unrivaled Accuracy and Reliability in More Than 100 ...

Masimo iSpO2 pulse oximeter and the iSpO2 app. Manufactured and submitted by Masimo Corp. (Irvine, CA). The iSpO2 is a measure-through-motion and low-perfusion pulse oximeter made for iPhone and iPad.